2017 News Releases

Webcast ImageWebcast - Replay
AtriCure, Inc. at Needham & Company’s 16th Annual Healthcare Conference
04/04/17 at 10:00 a.m. ET
AtriCure, Inc. at Needham & Company’s 16th Annual Healthcare Conference
Tuesday, April 4, 2017 10:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
Q4 and Full Year 2016 AtriCure, Inc. Earnings Conference Call
02/28/17 at 4:30 p.m. ET
Q4 and Full Year 2016 AtriCure, Inc. Earnings Conference Call
Tuesday, February 28, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
AtriCure, Inc. at the Leerink Partners Global Healthcare Conference
02/16/17 at 9:30 a.m. ET
AtriCure, Inc. at the Leerink Partners Global Healthcare Conference
Thursday, February 16, 2017 9:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
04/25/17AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
AtriClip is the most widely used device globally for left atrial appendage management MASON, Ohio--(BUSINESS WIRE)--Apr. 25, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold more than 100,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, which makes it the most widely used of all d... 
Printer Friendly Version
04/07/17AtriCure to Announce First Quarter 2017 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Apr. 7, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2017 financial results on Thursday, May 4, 2017. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, May 4, 2017 to discuss its first quarter 2017 financial results.... 
Printer Friendly Version
03/21/17AtriCure Names Two New Members to its Board of Directors
MASON, Ohio--(BUSINESS WIRE)--Mar. 21, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that Regina Groves and B. Kristine Johnson have been appointed to its Board of Directors. In addition, the company announced that Michael Hooven and Karen Robards, two existing members of the Board of Directors, will not stand for re-elect... 
Printer Friendly Version
03/14/17AtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial
MASON, Ohio--(BUSINESS WIRE)--Mar. 14, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr. David B. DeLurgio as the national principal investigator (PI) for the CONVERGE IDE clinical trial. Dr. DeLurgio is a cardiac electrophysiologist at Emory Healthcare in Atlanta, GA. He is Director of Electrophysiology... 
Printer Friendly Version
03/10/17AtriCure to Present at the Needham & Company’s 16th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Mar. 10, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Needham & Company’s 16th Annual Healthcare Conference at the Westin Grand Central Hotel in New York City on Tuesday, April 4, 2017. Management is scheduled to present at 10:00 a.m. Eastern Time. A live audio webcas... 
Printer Friendly Version
03/06/17AtriCure Announces hiring of Senior Vice President of Clinical, Regulatory, and Scientific Affairs
MASON, Ohio--(BUSINESS WIRE)--Mar. 6, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has hired Vinayak (Vini) Doraiswamy, PhD as its Senior Vice President of Clinical, Regulatory, and Scientific Affairs. Most recently, Dr. Doraiswamy served as Vice President of Global Clinical Operations at St. Jude Medical. In his role... 
Printer Friendly Version
02/28/17AtriCure Reports Fourth Quarter and Full Year 2016 Financial Results
2016 revenue of $155.1 million – up 19.5% 2016 U.S. sales of $122.4 million – up 19.7% 2016 International sales of $32.7 million – up 18.8% MASON, Ohio--(BUSINESS WIRE)--Feb. 28, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter and full year 2016 financial results. ... 
Printer Friendly Version
02/03/17AtriCure to Announce Fourth Quarter and Full Year 2016 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Feb. 3, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2016 financial results on Tuesday, February 28, 2017. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, February 28, 2017 to discuss its fourth quarter and full... 
Printer Friendly Version
01/24/17AtriCure to Present at the Leerink Partners Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Jan. 24, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Leerink Partners Global Healthcare Conference at the Palace Hotel in New York City on Thursday, February 16, 2017. Management is scheduled to present at 9:30 a.m. Eastern Time. A live audio webcast of the presentat... 
Printer Friendly Version
01/09/17AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2016
MASON, Ohio--(BUSINESS WIRE)--Jan. 9, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the fourth quarter and full year 2016 and provided 2017 financial guidance. Preliminary and unaudited revenue for fourth quarter 2016 is expected to be approximately $41.2 million, reflecting growth of... 
Printer Friendly Version